CR1

Kriya Provides Update on Pipeline Progress Ahead of Company Presentation at 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Monday, January 8, 2024
Continuity, Diabetes, Entrepreneurship, Risk, C3, Non-alcoholic fatty liver disease, Epilepsy, FDA, CR2, Anticonvulsant, Inflammation, Neuron, Geographic atrophy, Conference, Paratriathlon, Pain, European, Disease, Cmax, Glycated hemoglobin, Trigeminal neuralgia, FGF21, Steatosis, Therapy, Computational biology, Exophthalmos, TED, Diplopia, Varenicline, Smoking, Injection, AAV, CNS, DSM-IV codes, Patient, Graves' ophthalmopathy, Medicine, Seizure, Glucokinase, Neurology, CR1, NASH, Insulin, Brain, GMP, Trigeminal nerve, Ophthalmology, Pathology, Fibrosis, Pharmaceutical industry

PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Kriya Therapeutics, Inc., ("Kriya") a biopharmaceutical company developing gene therapies for common diseases affecting millions of people around the world, today provided an update on its pipeline of gene therapies for prevalent conditions including geographic atrophy, thyroid eye disease, diabetes, NASH, trigeminal neuralgia and epilepsy. Kriya is advancing the first of its gene therapy product candidates into the clinic in 2024 and expects up to five programs in the clinic by the end of 2025.

Key Points: 
  • Kriya’s pipeline includes gene therapies across three major therapeutic areas: ophthalmology, metabolic disease and neurology.
  • Its programs share the following features: direct-to-tissue delivery, validated biology, de-risked clinical and regulatory paths and large commercial markets.
  • Dr. Ramaswamy will share further information on Kriya’s portfolio during his presentation at the J.P. Morgan 42nd Annual Healthcare Conference on Tuesday, January 9th at 9:00 AM PT in San Francisco, California.
  • A significant proportion of patients suffer from refractory epilepsy, many of whom are candidates for invasive neurosurgery.

LASFIT AIR Wraps Up 2023 with Festive Cheer, Innovative Inflator Gaining Celebrity Approval

Retrieved on: 
Thursday, December 21, 2023
Ultimate, AIR, Attention, CR1, Multimedia, Motorcycle, Companion, LPM, LOS, Driver, Confidence, Christmas, Safety, Pressure, PSI, Road

LOS ANGELES, Dec. 21, 2023 /PRNewswire/ -- As the year gracefully winds down, LASFIT AIR reflects upon a year of triumphs, innovations, and unwavering commitment to customers. In the pursuit of excellence, LASFIT AIR have not only introduced groundbreaking products but have also solidified their position as a trusted companion for every traveller.

Key Points: 
  • LOS ANGELES, Dec. 21, 2023 /PRNewswire/ -- As the year gracefully winds down, LASFIT AIR reflects upon a year of triumphs, innovations, and unwavering commitment to customers.
  • Since its inception, LASFIT AIR has garnered the attention and recognition of millions of users.
  • LASFIT AIR is dedicated to revolutionising air inflation technology and providing dependable solutions to enhance the safety and convenience of travellers during their journeys.
  • With a commitment to innovation and user-centric design, LASFIT AIR aims to be the trusted companion for all your adventures.

LASFIT AIR Unwraps Festive Delights: Christmas Campaign and Innovative Tire Inflator Choices

Retrieved on: 
Wednesday, December 6, 2023
Confidence, Travel, CR1, LOS, AIR, TK1, Tire manufacturing

LOS ANGELES, Dec. 6, 2023 /PRNewswire/ -- Embracing the festive cheer, LASFIT AIR, the dynamic sub-brand specialising in air inflation technology of LASFIT, joyfully announced its Christmas campaign on December 5th, offering exclusive benefits for customers. Since the brand was born, it has enriched its innovative product lineup with TK1 AirMaster Tire Inflator for Off-Road, CR1 40s Fast Tire Inflator for Cars and BM1 Mini Tire Inflator for Riders.

Key Points: 
  • LOS ANGELES, Dec. 6, 2023 /PRNewswire/ -- Embracing the festive cheer, LASFIT AIR , the dynamic sub-brand specialising in air inflation technology of LASFIT, joyfully announced its Christmas campaign on December 5th, offering exclusive benefits for customers.
  • Since the brand was born, it has enriched its innovative product lineup with TK1 AirMaster Tire Inflator for Off-Road, CR1 40s Fast Tire Inflator for Cars and BM1 Mini Tire Inflator for Riders.
  • In the spirit of the season, LASFIT AIR unwraps a dedicated Christmas-themed landing page – a delightful shopping guide.
  • TK1 AirMaster Tire Inflator for Off-Road: Your Trusted Travel Companion
    Revolutionising air inflation, TK1 AirMaster Tire Inflator stands as a symbol of reliability.

Kriya Announces Exclusive License and Collaboration Agreement with Everads to Advance Gene Therapies for Prevalent Diseases in Ophthalmology Including Geographic Atrophy

Retrieved on: 
Wednesday, September 27, 2023
Drug delivery, Retina, Injection, CR2, Pediatrics, IgG4-related ophthalmic disease, Sclera, Eye, Geographic atrophy, Quality of life, Intravitreal injection, Inflammation, AAV, Complement, RESEARCH, Administration, C3, Choroid, Stanford University School of Medicine, Patient, CR1, PARK, Entrepreneurship, FDA, Therapy, Emotional dysregulation, Disease, Pharmaceutical industry, Medical device, Vaccine, Ophthalmology, Kriyā, C5

PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Kriya Therapeutics, Inc. ("Kriya"), a biopharmaceutical company developing gene therapies for conditions affecting millions of people around the world, has entered into an exclusive license, collaboration and supply agreement with Everads Therapy, Ltd (“Everads”) to advance Kriya’s portfolio of gene therapies for retinal diseases using Everads' suprachoroidal delivery device. Everads is a private biotech company that has developed a novel technology enabling targeted delivery of therapies to the retina via the suprachoroidal space, an anatomical compartment located between the sclera and choroid that traverses the circumference of the posterior segment of the eye. Suprachoroidal delivery is an emerging, non-surgical route of administration in ophthalmology. Specifically in delivery of gene therapy, this route of administration offers the potential to enhance the efficiency of gene therapy delivery to the retina while minimizing intraocular inflammation.

Key Points: 
  • Specifically in delivery of gene therapy, this route of administration offers the potential to enhance the efficiency of gene therapy delivery to the retina while minimizing intraocular inflammation.
  • The transaction enables Kriya’s access to Everads’ suprachoroidal delivery technology to deliver multiple prespecified gene therapy product candidates for several ophthalmic diseases, including those involving the complement cascade.
  • “I am quite optimistic and convinced that innovative therapies will continue to improve the lives of people with geographic atrophy and other serious ophthalmic diseases.
  • A gene therapy targeting the C3 and C5 pathways delivered by a suprachoroidal injection may be a significant improvement in the treatment of geographic atrophy.”

Results of Pre-MEASURE Study By NMDP/Be The Match, CIBMTR, and the NHLBI Published in JAMA

Retrieved on: 
Tuesday, March 7, 2023
Research, Genetics, Biotechnology, Other Health, Health, General Health, Other Science, Science, Oncology, HCT, Senior, MD, Center for International Blood and Marrow Transplant Research, Society, ASCO, Physician, JAMA, National Marrow Donor Program, MRD, Infection, Lung, Journal, DOI, NCI, Bangladesh Technical Education Board, Doctor of Philosophy, Acute myeloid leukemia, NHLBI, Hematopoietic stem cell transplantation, American Society of Clinical Oncology, Director of the National Institutes of Health, AML, American Medical Association, Dillon, United States Public Health Service, National Cancer Institute, Patient, Partnership, Risk, Annual general meeting, National Institute of Allergy and Infectious Diseases, Medicine, FRCP, Survival, National Heart, Lung, and Blood Institute, NGS, NIAID, RIC, DM, NMDP, NPM1, Laboratory, CR1, NIH, Medical device, Dentistry

It provides valuable insight into MRD as a predictive tool to inform HCT decisions and individualize treatment to improve outcomes.

Key Points: 
  • It provides valuable insight into MRD as a predictive tool to inform HCT decisions and individualize treatment to improve outcomes.
  • Unlocking the potential of precision medicine to improve it further will require a firm foundation of evidence.
  • The Pre-MEASURE study is the largest cohort of next-generation sequencing-based MRD testing (NGS-MRD) prior to allogeneic HCT for AML to date.
  • This content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

SELLAS Life Sciences Reports Second Quarter 2021 Financial Results and Provides Business Update

Retrieved on: 
Thursday, August 12, 2021
PD-1, Blood, USPTO, Clinical trial, WT1, MPM, SLS, TNBC, Patent, Memorial Sloan Kettering Cancer Center, Growth, Progression-free survival, Union, Merck Sharp & Dohme Federal Credit Union, Doctor of Science, Immunotherapy, NPS, Time, MRD, Company, Hematopoietic stem cell transplantation, Pembrolizumab, SEC, D, Merck & Co., Annual report, Technology transfer, Cancer, Baylor University Medical Center, CR1, Standard of care, Lymphatic system, MD, Nivolumab, COVID-19, DCR, Ovarian cancer, NEW, Position, Merck, HER2, NASDAQ, Pemetrexed, Terminology, Research, Bristol Myers Squibb, Drug development, OS, Probability, Survival, Russell, GLOBE, Acquisition, Patient, European Union, Second, PFS, Diagnosis, GPS, AML, Corporation, Cryptocurrency, Pharmaceutical industry, Dentistry

NEW YORK, Aug. 12, 2021 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) ("SELLAS" or the “Company”), a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapies for a broad range of indications, today reported its financial results for the quarter ended June 30, 2021 and provided a business update.

Key Points: 
  • (NASDAQ: SLS) ("SELLAS" or the Company), a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapies for a broad range of indications, today reported its financial results for the quarter ended June 30, 2021 and provided a business update.
  • Financial Results for the Second Quarter 2021:
    Licensing revenue: Licensing revenue was $1.9 million for the second quarter of 2021 and $7.6 million for the first half of 2021 which consists of the recognition of revenue from the Companys license agreement with 3D Medicines.
  • R&D Expenses: Research and development expenses for the second quarter of 2021 were $3.5 million, as compared to $2.3 million for the same period in 2020.
  • About SELLAS Life Sciences Group, Inc.
    SELLAS is a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapeutics for a broad range of indications.